Could a special MRI spot brain lymphoma without a biopsy?
NCT ID NCT04656431
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and researchers measure safety, image quality, and how well the scan identifies tumors. The study includes people with relapsed or newly diagnosed lymphoma to see if the method can also track treatment response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hyperpolarized carbon-13 pyruvate given intravenously before MRI
- What this could lead to
- If successful, this imaging technique could offer a new, non-invasive way to detect brain lymphoma and monitor how well treatment is working.
- What could go wrong
- This is a small, early-phase feasibility study focused on safety and image quality, not yet on patient outcomes. The technique may not prove sensitive enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.